Anika Therapeutics wins FDA nod for bone void filler

Anika Therapeutics (NSDQ:ANIK) said today that it won 510(k) clearance from the FDA for its hyaluronic acid-based bone void filler

The indication covers filling bone voids or defects that aren’t intrinsic to the stability of the bone, created during surgery or the result of traumatic injury. Made of a synthetic, biocompatible bone graft substitute material, the filler is injected into a void and hardens at body temperature. It’s then resorbed and replaced by new bone growth.

Get the full story at our sister site, Drug Delivery Business News.

The post Anika Therapeutics wins FDA nod for bone void filler appeared first on MassDevice.

from MassDevice http://ift.tt/2pKVWd2